This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Salix Pharmaceuticals Reports 2Q2012 Results

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the second quarter ended June 30, 2012 and other business updates.

Total product revenue was $181.0 million for the second quarter of 2012, a 36% increase compared to $133.2 million for the second quarter of 2011. Total product revenue for the first six months of 2012 was $352.1 million, a 47% increase compared to $239.1 million for the first six months of 2011. XIFAXAN ® revenue for the second quarter of 2012 was $116.7 million, a 34% increase compared to $87.0 million for the second quarter of 2011. XIFAXAN revenue for the first six months of 2012 was $229.6 million, a 37% increase compared to $167.7 million for the first six months of 2011. APRISO ® revenue for the second quarter of 2012 was $21.8 million, a 45% increase compared to $15.0 million for the second quarter of 2011. The combined revenue contribution of our most recently-introduced products - RELISTOR ®, SOLESTA ® and DEFLUX ®- totaled $19.2 million for the second quarter of 2012.

Total cost of products sold was $33.3 million for the second quarter of 2012 and $67.4 million for the first six months of 2012, compared to $25.2 million for the second quarter of 2011 and $43.8 million for the first six months of 2011. Gross margin on total product revenue was 81.6% for the second quarter of 2012 compared to 81.0% for the second quarter of 2011, and 80.8% for the first six months of 2012 compared to 81.7% for the first six months of 2011. Research and development expenses were $27.2 million for the second quarter of 2012 and $53.9 million for the first six months of 2012, compared to $29.5 million and $60.5 million, respectively, for the prior year periods. Selling, general and administrative expenses were $65.3 million for the second quarter of 2012 compared to $44.7 million for the prior year period and $125.7 million for the first six months of 2012 compared to $91.3 million for the prior year period. The increase in selling, general and administrative expenses for 2012 compared to 2011 is due primarily to increased personnel costs related to our institutional sales force and our office-based sales force expansions and increased marketing expenses related to RELISTOR and SOLESTA. The Company reported GAAP net income of $20.1 million, or $0.32 per share, fully diluted, for the second quarter of 2012 and $30.1 million, or $0.47 per share, fully diluted, for the-six month period ended June 30, 2012.

1 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs